Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

ANRS, Emerging Infectious Diseases: Clinical Trials & FDA Approval Profile

ANRS, Emerging Infectious Diseases (Global / Institutional) sponsors 32 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (8 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.4%
Median Closed Enrollment vs National (145 pts)267 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for ANRS, Emerging Infectious Diseases
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)32
Active Pipeline (Recruiting Now)13 (8)
Completed vs Stopped Early7 / 3 (9.4%)
Median Closed Actual Enrollment267 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With ANRS, Emerging Infectious Diseases
Hospital Research SiteLocationShared Protocols
Hôpital Saint LouisParis2
Hôpital Saint-AntoineParis2

Explore interactive annual charts and M&A subsidiary rollups in the ANRS, Emerging Infectious Diseases Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI